Philip Mease, MD, is Clinical Professor at the University of Washington School of Medicine in Seattle, Director of the Rheumatology Clinical Research Division of Swedish Medical Center. His clinical practice is based at Seattle Rheumatology Associates. He conducts clinical trials of emerging therapies for rheumatic diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, fibromyalgia, osteoarthritis and lupus. He conducts research in disease state metrics and is the Co-Chair of three working groups of OMERACT (Outcome Measures in Rheumatology Clinical Trials) on psoriatic arthritis, fibromyalgia and single joint assessment, as well as being a member of the Soluble Biomarker working group. He is a founding organizer and President of GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis), and a member of SPARTAN (Spondyloarthritis Research & Treatment Network).

Dr. Mease received his undergraduate and medical degrees from Stanford University. He completed his residency in internal medicine at the University of Washington School of Medicine, where he also served as chief resident and fellow in rheumatology.  He is the author of over 150 journal articles and 13 book chapters in texts including Biologics in General Medicine (Springer-Verlag, 2007), Update in Targeted Therapies in Rheumatology (Lippincott, 2007), and Rheumatology (2010). He serves as a reviewer for a number of journals including Arthritis & Rheumatism; Arthritis Care & Research; Annals of the Rheumatic Diseases; Journal of Rheumatology; Journal of the American Academy of Dermatology, Seminars in Arthritis and Rheumatology; Journal of Clinical Investigation, Best Practice & Research Clinical Rheumatology; Journal of Experimental and Clinical Rheumatology; and Journal of Musculoskeletal Medicine.  He has been the recipient of the Medical Communicator Award of the American College of Rheumatology.